News archive for Neurotargeting Research Group
Ebselen, a promising drug candidate against cancer, bipolar disorder and the virus infection Covid-19, covalently bonds to cysteine residues in 14-3-3 adaptor proteins, triggering 14-3-3 destabilization and degradation in cells and intact brain tissue when used in therapeutic concentrations, potentially explaining the behavioral and anti-neoplastic effects of this drug.
Our research project BIOPROM (Biomimetic Proteolipid Multilayers - Structure and Properties) was awarded a research grant of 12 MNOK by the Research Council of Norway. The BIOPROM project will reveal unprecedented details of the molecular structure and properties of myelin, from the nano to the meso scale.
- February 2024 (2)
- June 2023 (1)
- November 2022 (1)
- April 2022 (1)
- March 2022 (3)
- February 2022 (2)
- September 2021 (2)
- August 2021 (1)
- April 2021 (1)
- March 2021 (1)
- February 2021 (2)
- February 2020 (1)
- January 2020 (1)
- September 2019 (1)
- February 2019 (1)
- January 2019 (3)
- November 2018 (1)
- October 2018 (1)
- July 2018 (1)
- June 2018 (1)
- June 2017 (1)
- January 2017 (1)
- October 2016 (1)
- September 2016 (1)
- October 2015 (1)